CAR T cell therapy has been transformative for refractory hematological malignancies in both children and adults, and CD19-targeting CAR T cells are now FDA-approved for treatment of acute lymphoblastic leukemias as well as other hematological cancers18. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.